BUSINESSBLOOMBERG
Roche’s Second-Quarter Sales Held Back by Blockbuster Eye Drug
Roche Holding's second-quarter sales were impacted by a slower-than-expected recovery of its blockbuster eye drug Vabysmo. Investors are anticipating a key new drug to drive future growth.
Mentioned
Related Signal
Adjacent reporting
- Roche First-Quarter Sales Drop, Hurt by Copycats and Currencies
- Novo Raises Forecast as Wegovy Pill Fuels Sales
- Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker
- STAT+: Hims’ sales miss as telehealth competition grows
- Why J&J thinks its new psoriasis pill could be one of its biggest drugs ever